Goodwin Advises OMass Therapeutics on $310 Million Series C

Professionals

Michael H. BisonKenny Walker-DurrantHattie Muncey

The Life Sciences team advised OMass Therapeutics on an oversubscribed $310 million Series C financing to advance its portfolio of small-molecule therapeutics in endocrinology and immunology. The round was co-led by new investors Bain Capital Life Sciences, Forbion, and Novo Holdings, with additional participation from Janus Henderson Investors, SV Health Investors, and Jefferson Life Sciences. Each of the company’s existing investors also participated in the round, including Syncona, Oxford Science Enterprises, GV, Northpond Ventures, Sanofi Ventures, British Business Bank, and University of Oxford. Proceeds from the financing will support the advancement of the company’s lead program, OMS1620, a potential best-in-class MC2 (melanocortin-2) receptor antagonist for the treatment of congenital adrenal hyperplasia (CAH) through Phase 2 development, as well as ACTH-dependent Cushing’s syndrome.

OMass Therapeutics is a biotechnology company developing small-molecule therapeutics against highly validated target ecosystems. Its proprietary OdyssION™ drug discovery platform combines next-generation native mass spectrometry, novel biochemistry techniques, and custom chemistry to interrogate drug targets within their native ecosystems, providing cell system fidelity with cell-free precision.

The Goodwin team was led by Michael Bison, Kenny Walker-Durrant, Hattie Muncey, Emma McIntyre, and Daisy Bolitho.

For more information on the deal, please read the press release.

Goodwin Advises OMass Therapeutics on $310 Million Series C

Related Content

SEC Issues Section 21(a) Report on Investor Coalitions, “Group” Formation, and Schedule 13G Eligibility

Sanofi and Regeneron Expand Immunology Collaboration in Deal Worth Up to $8 Billion

Celltrion Launches Omalizumab Biosimilar in the United States

Sandoz and mABxience Announce Collaboration for Proposed Emicizumab Biosimilar

Stopping Disputes Before They Derail Innovation: The Emerging Role of Life Sciences Dispute Review Boards

Biocon’s Pertuzumab Biosimilar Receives Positive CHMP Opinion Under EMA’s Tailored Clinical Approach

Nektar v. Lilly: Lilly Defeats CRE Claim, but Jury Finds It Owes $90M for Breaching the Implied Covenant of Good Faith and Fair Dealing

Preliminary Injunctive Relief in Trade Secret Cases: When to Move and What to Prove

Goodwin’s UK Platform Highly Ranked in Chambers UK 2027

Goodwin Advises TRex Bio on Intellectual Property Aspects for $117 Million Initial Public Offering

Barry Z. Bazian Named to American Bankruptcy Institute’s 40 Under 40

Goodwin Advises BioGeneration Ventures, Angelini Ventures, and Kurma Partners on $58 Million Series A Financing of RougeTx

Goodwin Advises Repligen Corporation on the Acquisition of BioLife Solutions

Goodwin Advises Alentis on Global Collaboration Agreement With CSL for $355 Million Upfront and Up to $1.2 Billion in Milestone Payments and Worldwide Profit Share

Naomi Birbach and Alicia Palladino Named 2026 Managing IP Rising Stars

Second Annual AI & Drug Discovery Symposium: Revolutionizing the Future of Medicine

Life Sciences